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Abstract 
Coenzyme Q~o (vitamin Qio) is biosynthesized in the human body and is functional in bioenergetics, anti-oxidation reactions, and in 
growth control, etc. It is indispensable to health and survival. The first double-blind trial was with twelve patients, ranging from 7-69 
years of age, having diseases including the Duchenne, Becker, and the limb-girdle dystrophies, myotonic dystrophy, Charcot-Marie-Tooth 
disease, and the Welander disease. The control coenzyme Qio (COQlo) blood level was low and ranged from 0.5-0.84 /xg/ml. They 
were treated for three months with 100 mg daily of CoQlo and a matching placebo. The second ouble-blind trial was similar with fifteen 
patients having the same categories of disease. Since cardiac disease is established to be associated with these muscle diseases, cardiac 
function was blindly monitored, and not one mistake was made in assigning CoQt 0 and placebo to the patients in both trials. Definitely 
improved physical performance was recorded. In retrospect, a dosage of 100 mg was too low although effective and safe. Patients 
suffering from these muscle dystrophies and the like, should be treated with vitamin Qwo indefinitely. 
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1. Introduction 
We have biochemically and clinically studied patients 
with muscular dystrophy for about twenty-five years. In 
the early years, with limited capsules of CoQl0, it was 
appropriate to treat openly certain cases of dystrophy and 
one of these cases was as follows. An adult with a late 
onset form of muscular dystrophy had been advised by his 
neurologist hat he should mentally prepare himself for a 
wheelchair within two years. He was a lawyer and with a 
devastated morale, he volunteered to be placed on oral 
CoQ~ 0. His neurologist remarked that if this patient could 
be kept out of a wheelchair for five years, we should take 
an even greater interest in CoQI0 to treat muscular dystro- 
phy. After not five, but six years, he not only was not in a 
wheelchair, but he would swim, bowl, and play golf 
frequently, and conducted a vigorous business life in his 
legal profession. 
Although they can be valid, such case reports are 
usually ignored or belittled, particularly by those without 
the biochemical and scientific background to make a 
judgement. In due time, we had enough capsules to con- 
duct double-blind trials which are summarized herein. 
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2. Studies in 1966-1970 on hexadydro-coenzyme Q4 
and coenzyme Q7 and mice with a muscular degenera- 
tion 
Michelson et al. [1] in 1955 described a mutation in 
mice with a muscular degeneration which resembled the 
progressive muscular dystrophy in humans. This sponta- 
neous autosomal mutation in mice, 129/Re, caused a 
muscular weakness, atrophy, and a reduced lifespan for 
these mice. West et al. [2] reported in 1966 that these mice 
showed histological and physiological similarities to the 
pseudo hypertrophic and myotonic dystrophy in man, the 
Erb dystrophy and the Duchenne dystrophy. 
In those years of the 1960s, coenzyme Qt0 was not yet 
abundantly available, but the synthetic hexahydro-coen- 
zyme Q4 and the natural coenzyme Q7 were available for 
animal studies. 
Farley et al. [3] treated these severely dystrophic mice, 
129/Re, with hexahydro-coenzyme Q4, and observed that 
they were physically improved, and could walk using all 
their legs. Later on Scholler et al. [4] recorded that when 
these dystrophic mice, 129/Re, were treated with hexahy- 
dro-coenzyme Q4, they could survive four times as long as 
the control mice. The level of CoQ9 in the hearts and hind 
legs of these mice, 129/Re, showed a deficiency (P  < 
0.01). 
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When these mice were treated with CoQ7 in the fifth 
month of their eight-month lifespan, their lifespan was 
doubled. Littarru et al. [5] recorded that oral CoQ7 reached 
the mitochondria in the hearts and hind legs of these mice. 
3. Association of cardiac disease with human dystro- 
phies and myotonias 
The medical iterature on human muscle disease records 
that an association of cardiac disease with muscle disease 
in dystrophic patients is firmly established. This cardiac 
aspect of muscle disease is so very important hat eight 
exemplary references over twenty-one years, 1963-1983, 
are cited [6-13]. For example, Welsh et al. [6] found 
cardiac disease in 73 patients with muscular dystrophy, 
including the Duchenne, limb-girdle, and fascioscapulo- 
humeral forms, and patients with dystrophia myotonica.  
Cardiac disease is associated with virtually every form 
of muscular dystrophy and myopathy. 
4. Superiority of impedance cardiography to monitor 
cardiac function in humans 
Impedance cardiography is a non-invasive, reproducible 
and quantitative measurement to monitor cardiac function 
over months of time. This technique has superiorities, as 
evaluated by Baker and Mistry [14] and by Baker [15] in 
comparison with conventional techniques to measure car- 
diac function. Impedance cardiography has been ideal to 
monitor the cardiac function of dystrophic and myotonic 
patients who were treated with vitamin Q~o, because the 
therapeutic trials were conducted over months of time. 
5. Two double-blind trials with CoQl0 and placebo in 
therapy of muscle disease 
In the first double-blind trial, twelve patients, ranging 
from 7-69 years of age, were representative of the pro- 
gressive dystrophies and the neurogenic atrophies, and 
included the Duchenne, Becker, and the limb-girdle dys- 
trophies, myotonic dystrophy, Charcot-Marie-Tooth dis- 
ease and the Welander disease. They were treated for three 
months with 100 mg daily of CoQ~ 0 and a matching 
placebo in a double-blind trial. The blood data are in Table 
1. 
Solely by statistically significant change or no change 
in the stroke volume and cardiac output, all eight patients 
on blind CoQ~o and all four patients on blind placebo were 
correctly assigned (P<0.003) .  An improved physical 
well-being was observed for 4 /8  treated patients and for 
0 /4  placebo patients. Of the placebo patients, 3 /4  later 
improved on CoQl0. The blood levels of CoQI 0 before the 
trial ranged from 0.5-0.84 /~g/ml, and for every patient 
there was a significant increase in the CoQi0 blood level 
on therapy with CoQ~o, and no increase on placebo. 
In retrospect, in 1994 the dosage of 100 mg of CoQ~ 0 
was too low, and the three-month trial in 1985 was too 
brief. 
A second double-blind trial with coenzyme Qi0 was 
conducted with fifteen patients with progressive muscular 
dystrophies and neurogenic atrophies which included the 
Duchenne, Becker, and limb-girdle dystrophies, myotonic 
dystrophy, Charcot-Marie-Tooth disease, fascioscapulo- 
humeral muscular disease, and congenital hypotonia nd 
Welander disease. The impaired cardiac function was non- 
invasively and extensively monitored. The cardiac function 
was significantly increased for all patients on CoQj0, and 
even to a normal  range for some of the patients. 
Table 2 exemplifies five of the fifteen patients on 
diagnosis, and the cardiac data during the double-blind and 
crossover trials. 
Table 3 contains the data on the blood levels of CoQl 0 
during the double-blind and the open trial on all fifteen 
patients. 
Table 4 summarizes the clinical observations on the 
physical performance particularly in regard to walking, 
running, and tiredness and fatigue. Although these physical 
improvements were subjective, they are apparently valid. 
Table 1 
First double-blind trial data nd blood data 
Patient (sex, age) Double-blind Average CoQi o blood level (/zg/ml) 
assignment code control blind open 
M.B. (F, 45) Placebo Placebo 0.63 0.61 
L.R. (M, 7) CoQio CoQio 0.62 1.11 
D.M. (M, 16) Placebo Placebo 0.58 0.61 
K.A.C. (M, 7) CoQio CoQto 0.50 1.94 
H.L.D. (F, 39) Placebo Placebo 0.68 0.63 
J.L.J. (M, 25) CoQi0 CoQt 0 0.71 1.22 
D.L.K. (M, 37) CoQI0 CoQi0 0.55 1.16 
W.P. (F, 69) Placebo Placebo 0.84 0.77 
H.M.K. (F, 63) CoQio CoQio 0.82 2.93 
B.H. (M, 31) CoQt0 CoQto 0.59 2.09 
M.D. (F, 63) CoQio CoQlo 0.68 1.96 
C.S. (F, 49) CoQio CoQio 0.78 1.58 
1.40 (CoQ Io) 
1.24 (CoQ~o) 
1.32 (CoQi 0) 
1.47 (CoQt 0) 
1.76 (CoQt0) 
1.13 (CoQi 0) 
2.13 (CoQio) 
1.12 (Placebo) 
1.43 (CoQlll) 
2.03 (CoQll I) 
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Table 2 
Exemplary patients with muscular dystrophy and neurogenic atrophy 
Patient, sex, age Functional 
Diagnosis datum 
Days of therapy: C a; D b; O ~ 
Test group results 
control " double-blind t, open c Qm; crossover 
1. J.A., M, 8 (A) 
Duchenne (B) 
96: 105; 182 (C) 
2. J.P.B., M, 43 (A) 
Limb-girdle (B) 
78; 102; 862 (C) 
3. D.C., M, 33 (A) 
Fascioscapulohumeral (B) 
30; 186:69 (C) 
4. D.H.. M, 54 (A) 
Charcot-Marie-Tooth (B) 
20; 126; 34 (C) 
5. P.K., F, 31 (A) 
Limb-girdle (B) 
34:481 ; 890 (C) 
6. M.R., M, 27 (A) 
Charcot-Marie-Tooth (B) 
14; 158; 68 (C) 
7. M.R,, F, 33 (A) 
Hypotonic (B) 
24; 118; 260 (C) 
8. T.A.W.. M, 14 (A) 
Becker's (B) 
16: 131:124 (C) 
9. J.M, F, 58 (A) 
Charcot-Marie-Tooth (B) 
(c) 
10. T.D., M, 31 (A) 
Limb-girdle (B) 
21 : 66; 667 (C) 
11. L.L., M, 38 (A) 
Myotonic (B) 
27: 172; 539 (C) 
12. T.E.P., M, 74 (A) 
Limb-girdle (B) 
19; 120; 721 (C) 
13. M.T., F, 69 (A) 
Limb-girdle (B) 
20; 150; 560 (C) 
14. B.H., F, 53 (A) 
Welander (B) 
22; 75; 695 (C) 
15. B.S., M. 15 (A) 
Becker's (B) 
31 ; 90; 348 (C) 
5.3 ± 0.7 5.6 ± 0.7; n.s. 6.6 ± 0.8; P < 0.001 
65±9 66± 16; n.s. 80±7;  P < 0.001 
80±9 86± 10;- 87±8; -  
5.3 ± 0.3 5.5 ± 0.3; n.s. 5.8 + 0.7; P < 0.001 
73 ± 5 75 ± 5: n.s. 73 ± 10; n.s. 
77 ± 2 73 ± 4: - 79 ± 5; - 
7.9_+0.7 8.1 ± 1.4; n.s. l l. l ± 1.4; P <0.001 
129± 1 132 ± 8; n.s. 168±21; P < 0.001 
64±4 63± 10;- 65±7; -  
7.9±0.8 8.1±0.7;n.s. 11.8_+2.3:P<0.001 
126 ± 14 129 ± 10; n.s. 186 ± 3l: P < 0.001 
62± l 61±2; -  78±4: -  
4.5 ± 0.4 5.4 ± 0.4; P < 0,001 6.2 ± 0.5: P < 0.001 
46±9 59±7;  P < 0.001 69±4:  P< 0.001 
99±9 9l ±5; -  89±5: -  
9.1 ± 0.8 12.2 ± 1.7; P < 0.001 11.9 ± 1.4; P < 0,001 
135± 17 188± 14; P < 0.001 195± 1l; P < 0.001 
68 ± 8 64 ± 5; - 62 ± 6; - 
6.9 ± 0.6 7.5 ±0.1; P < 0.001 10.4 ± 2. l; P < 0,001 
82±6 95±5:  P < 0.001 124± 19; P < 0.001 
84±7 79±5: -  83±6; -  
6. l ±0.5 7.3±0.7; P < 0.001 9.7± 1.7; P < 0,001 
57.2 ± 11 74 ± 7: P < 0.001 97 ± 15; P < 0.001 
104 ± 2 99 ± 4; - 99 ± 3; - 
5.0 ± 0.9 5.5 ± 0.9; n.s. 6.6 ± 1.7; P < 0,001 
60 ± 9 57 ± 9; n.s. 70 + 16; P < 0.001 
84+_2 98±6-  93±5: -  
3.8 ± 0.3 4.8 ± 0.7; P < 0.001 5.6 ± 0.5; P < 0,001 
46±4 68±5;  P < 0.001 72±6;  P < 0.00t 
83 ± 4 72 ± 2; - 77 ± 2: - 
3.0 ± 0.4 3.4 ± 0.3; n.s. 3.7 ± 0.4; P < 0.01 
50±7 60±4;  P < 0.01 65±5;  P < 0.001 
61±8 58±6; -  57±7: -  
2.7 ± 0.6 3.4 ± 0.3; P < 0.01 3.3 ± 0.4; P < 0.001 
41±8 52±4;  P<0.01 51±4:P<0.001 
65 ± 2 65 ± 5; - 69 ± 5: - 
3.2 ± 0.5 3.5 ± 0.3: n.s. 4.9 ± 0.9; P < 0.001 
39±6 41±4;n.s .  56±8;  P<0.001 
81 ±3 85±6; -  87±6; -  
3.2 ± 0.5 4.6 ± 0.4; P < 0.001 4.2 ± 0.3; P < 0.001 
43 ± 4 62 _+ 3; P < 0.001 55 ± 8; P < 0.001 
75 ± 6 74 ± 7; - 77 ± 7: - 
8.1 ± 1.2 9.1 ± t.5; n.s. 11.5 ± 2.5; P < 0.001 
96±11 115 ±8; P<0.001 130±27;P<0.001 
84 + 5 79 ± 9; - 84 ± 6; - 
Functional data; Mean ± S.D, (A) cardiac 
a Control. 
b Double-blind period of study. 
Open period of study. 
output (CO), 1/min; (B) stroke volume (SV), ml/beat; (C) heart rate (HR), beat/min 
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Table 3 
Results of double-blind and open trial data and blood data 
No. Patient; sex, age (y) Double Blind CoQI o blood levels average (/zg/ml) 
Assignment Code Control Blind Crossover 
1. J.A.; M, 8 Placebo Placebo 0.61 0.53 1.62 
2. J.P.B; F, 43 Placebo Placebo 0.72 0.84 2.48 
3. D.C.; M, 33 Placebo Placebo 0.94 0.75 1.68 
4. D.H.; M, 54 Placebo Placebo 0.89 0.83 0.94 
5. P.K.; F, 31 CoQi o CoQt 0 0.66 2.24 2.84 
6. M.R.; M, 27 CoQm CoQm 0.64 1.05 1.17 
7. M.R.; F, 33 CoQi 0 CoQm 0.74 1.81 1.27 
8. T.A.W.; M, 14 Placebo Placebo 0.81 0.82 1.42 
9. J.M.; F, 58 Placebo Placebo 0.93 1.00 2.05 
10. T.D.; M, 31 CoQI 0 CoQt 0 t.17 2.74 2.48 
11. L.L.; M, 38 CoQi 0 CoQt o 0.65 1.85 1.72 
12. T.E.P.; M, 74 CoQi 0 CoQm 1.04 2.29 2.45 
13. M.T.; F, 69 Placebo Placebo 0.90 0.80 1.70 
14. B.H.; F, 53 CoQi 0 CoQi 0 0.95 2.20 2.50 
15. B.S.; M, 15 CoQI o CoQt 0 0.58 1.38 1.44 
Mean + S.D. 0.81 ___ 0.17 P < 0.001 1.85 _+ 0.56 
Four patients (Nos. 6,7,11,15) who were blindly treated 
with CoQl0 did not show a significant increase in blood 
levels of CoQl0 on 100 mg of CoQ10, and which were 
above 2.0 /zg/ml. Four other patients [5,10,12,14] showed 
increases in the blood levels of CoQl0 which were above 
2.0 /zg/ml, but less than 3.0 /xg/ml. It is evident hat the 
dosage of 100 mg of CoQl0 daily for the fifteen patients 
with dystrophies and atrophies was too low. In a future 
trial with a daily dosage of 300 to 400 mg, the improve- 
ment in metabolic and physical performance would be 
even more impressive. 
The basis for the increased osage is as follows. 
body. There is no effective treatment of such patients with 
dystrophies and atrophies with drugs in medicinal chem- 
istry which are foreign to the human body. 
This beneficial therapy may be considered as a 
'breakthrough in medicine' and it is appropriate to explain 
the apparent scientific and medical success. 
6.3. The biosynthesis of CoQ1 o from phenylalanine 
The steps in the sequence for the biosynthesis of vita- 
min Ql0 from phenylalanine in the human body have eight 
aromatic intermediates; Friis et al. [17]. 
6. Clinical data on dosage of vitamin QlO 
Langsjoen et al. [16] administered an average dose of 
225 mg per day of CoQ10 to a total of 109 patients in 
cardiology. The increase in the blood level of CoQ10 on 
treatment was considered therapeutic at 3.0 /xg/ml. 
6.1. Vitamin deficiency diseases 
Based on the clinical research of Yuichi Yamamura in 
Japan and Per Langsjoen of Texas and others, heart failure 
may be classified as a vitamin deficiency of coenzyme 
Ql0'  
6.2. Significance of the successful therapy with vitamin Q io 
of muscular dystrophies and neurogenic atrophies 
It has been established that therapy with vitamin Ql0 of 
patients with muscular dystrophies and neurogenic atro- 
phies improves their metabolic and physical capacities. 
This beneficial therapy is academically based upon bio- 
chemical mechanisms which are intrinsic to the human 
Tyrosine ~ COOH 
H 0 ..--'q..,.~.~ NH2 
5,6,2,8-tetrahydrobiopterin 
vitamin 136 
vitamin C 
vitamin B2 
folio acid 
vitamin BI2 
niacinarnide 
pantothenic a id 
trace elements 
o 
CH,50 CH 2 C ~ H I "  C'~ CH2"~ 
o L cI.~ J,o 
CH~O ¢H3 H 
' .j o 
Vi tamin  QI0 
Scheme 1. Required vitamins for biosynthesis of vitamin Qm in human 
tissue. 
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Table 4 
Clinical observation on physical performance 
285 
No. Patient Sex Age Diagnosis Improvements 
1 J.A. M 8 Duchenne 
4 D.H. M 54 Charcot-Marie-Tooth 
5 P.K. F 31 Limb-girdle 
6 M.R. M 27 Charcot-Marie-Tooth 
8 T.A.W. M 14 Becker' s
9 J.M. F 58 Charcot-Marie- Tooth 
11 L.L M 38 Myotonic 
t 5 B.S. M 15 Becker's 
Became more active physically and could walk and run better 
Better muscular performance and longer exercise 
Obese, but less tiredness after physical movement 
Excellent improvement in physical movement; less tiredness 
Easier to arise from wheelchair; can walk better and longer 
Became stronger; walk better alone; exercise longer with less fatigue 
Move unaided better; can step stronger and walk longer 
Can run and jump much better and longer and play some basketball 
6.4. The vitamins required for the biosynthesis of vitamin 
Q:o in the human body 
Scheme 1 shows that there are at least eight other 
vitamins, and trace elements, that are required in the 
human body to convert the amino acid, tyrosine, into 
vitamin Q~0. These eight common vitamins have vital 
biochemical functions in the human body in addition to 
their function in the biosynthesis of vitamin Q~0. Probably, 
countless people have in their bodies deficiencies of these 
eight vitamins and trace elements, which range from negli- 
gible to major. Such deficiencies can occur in all the issues 
and organs of the human body. The great range of these 
deficiencies in terms of the individual vitamins, and the 
ratios of those vitamin deficiencies which are metaboli- 
cally related, allow a great diversity of all these deficien- 
cies. The diversified forms of the dystrophies and the 
atrophies are possibly - -  even probably - -  correlated with 
these complex vitamin deficiencies over the entire human 
body. The diversified dystrophies and atrophies can be a 
predominant metabolic result of these very complex vita- 
min deficiencies. 
Since our clinical studies have demonstrated that vita- 
min Q~0 is therapeutically beneficial to a range of dystro- 
phies and atrophies, it appears that a deficiency of vitamin 
Ql0 is paramount in muscular disease, and probably be- 
cause of the essentiality of vitamin Ql0 in the bioener- 
getics of life. 
6.5. A conclusion on the therapy with vitamin Qlo of 
muscular dystrophies and neurogenic atrophies 
It is now evident that muscular dystrophies have a 
deficiency of vitamin Ql0. Oral therapy with vitamin Qt0 
can reduce or eliminate the symptoms of these muscular 
diseases, and restore a well-being and physical capacity 
which have frequently been normal. However, the most 
effective daily dosage of vitamin Qi0, and the best formu- 
lations for such patients remains to be determined. 
6.6. The dysfunction of DNA: essentiality of vitamins 
Certain vitamins are essential for the biosynthesis of the 
DNA bases which are adenine, thymidine, cytosine, and 
guanine. A deficiency of vitamin B 6 can  cause a deft- 
ciency of thymidine. The vitamin forms of folic acid are 
required for the biosynthesis of both guanine and adenine. 
Nicotine adenine dinucleotide is required for the biosyn- 
thesis of both cytosine and thymidine. 
A deficiency of only thymidine can result in mutations 
of DNA and cause the initiation of cancer. 
Therefore, cancer may be initiated by deficiencies of 
one or more DNA bases, and be classified as a malfunction 
of genetics. However, the initial biochemical dysfunctions 
may actually be deficiencies of one or more vitamins, and 
which are so readily corrected with such profound benefit. 
7. Overview 
congestive heart failure, CHF, is a major disease. 
Biomedical and clinical research as demonstrated that the 
therapy of CHF with vitamin Qt0 can be restorative, and 
partially or entirely displace cardiovascular drugs. The 
diverse muscular dystrophies are diseases of substantial 
magnitude which have cardiac dysfunction. The Merck 
Manual, 1992, states "there is no drug for the specific 
therapy of these muscular dystrophies", and recommends 
"exercise should be encouraged". Our research has 
demonstrated by two double-blind trials over several years 
that therapy of the muscular dystrophies with vitamin Ql0 
can be restorative. An apparent basic principle is now 
evident which is as follows: 
Congestive heart failure and the muscular dystrophies 
have a common deficiency of vitamin Q10- The muscular 
dystrophies may also have one or more significant vitamin 
deficiencies of those vitamins required in the biosynthesis 
of CoQl 0, and that these additional diverse deficiencies 
may be major for the dystrophies, but be trivial for conges- 
tive heart failure. 
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